Interview 25 Sep 2017 Meet the Founder & CEO of Galapagos, Europe’s Biotech Role Model Onno van de Stolpe founded Galapagos nearly 20 years ago and still is CEO of this European biotech success story. I caught up with him for the full story. It was when he was studying at the agricultural university in Wageningen, The Netherlands, when “I got fascinated by molecular biology, and the biotech industry in […] September 25, 2017 - 10 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 23 Aug 2017 Dutch Biotech could treat Dyslipidemia with Belgian Nanobody Argenx’ partner Staten Biotechnology has published results that present a drug licensed from the Belgian biotech as a promising approach to control blood lipid levels. Staten Biotechnology is a young biotech in Breda, the Netherlands, focusing on treating dyslipidemia and reduce cardiovascular mortality and backed by BioGeneration Ventures and Forbion Capital Partners as investors. Back […] August 23, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 10 Aug 2017 Belgian Biotech Takes Down Untreatable Lung Disease in Phase II, Eyes the Market Galapagos’ GLPG1690 wowed analysts with efficacy and tolerability data in idiopathic pulmonary fibrosis treatment, opening the door to the market. Galapagos, based in Mechelen, Belgium, has reported a win in Phase IIa for its candidate GLPG1690, which aims to treat patients with idiopathic pulmonary fibrosis (IPF). The median survival is 2 to 5 years after […] August 10, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2017 Sanofi Offers up to €2.4Bn to Belgian Biotech to Develop Nanobodies Ablynx and Sanofi have entered a research collaboration and exclusive licensing agreement for up to eight nanobody candidates for immune and inflammatory disease. Ablynx, based in Belgium, develops nanobodies, single-domain antibodies inspired on those of camels and llamas that have the advantage of being much smaller than standard antibodies. This technology has caught the attention of Sanofi, […] July 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2017 Galapagos and Gilead Launch the Fifth New Trial for Filgotinib this Year With the addition of uveitis, Galapagos and Gilead are raising to 10 the number of indications in filgotinib’s clinical pipeline. Galapagos and Gilead clearly have big expectations for filgotinib. The small molecule is already in Phase III for rheumatoid arthritis, Crohn’s disease and ulcerative colitis. The team is now launching a new Phase II trial in […] July 5, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2017 Belgian Biotech Starts Phase Ib with an off-the-shelf mRNA Therapy for Melanoma eTheRNA has started a Phase Ib trial in patients with melanoma to test a cancer immunotherapy based on off-the-shelf mRNA technology. eTheRNA is one of the few companies working in mRNA therapies that are running clinical trials. The Belgian biotech has announced the start of a Phase Ib trial with its candidate TriMix-MEL, also called ECI-006, in patients […] June 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jun 2017 New Belgian Biotech will use Microorganisms to Replace Pesticides and Fertilizers Aphea.Bio has gathered a total of €9M in funding to start working on a new technology to produce biopesticides and biostimulants for European agriculture. Belgium has a new biotech that will be dedicated to developing sustainable, microorganism-based biopesticides and biostimulants. Aphea.Bio has raised €7.7M in a Series A round led by the Belgian life sciences investor V-Bio Ventures in addition to a €1.3M grant […] June 26, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 20 Jun 2017 Belgian Llama Antibody Developer gets Second Preclinical Milestone from Danish Pharma argenx’s 2015 deal with Leo Pharma for anti-inflammatory antibodies continues to pay off, though it hasn’t been disclosed by how much exactly. Two years ago, Ghent-based argenx and Danish Leo Pharma teamed up to develop antibodies to counter inflammatory diseases in a deal totalling €105M. argenx just received its second preclinical milestone for granting Leo access to […] June 20, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Startup Scout 2 Jun 2017 This French Biotech Wants to Reinvent DC-based Immunotherapies This week we had the chance to visit both Grenoble and Liège, where the French-Belgian biotech hybrid PDC*line Pharma has its two headquarters. The company is progressing new types of immunotherapies based on dendritic cells (DCs). Mission: PDC*line Pharma emerged from an R&D program of the French Blood Bank (EFS, Etablissement Français du Sang), where […] June 2, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 22 May 2017 UPDATE: Argenx’s IPO soars to over €100M to prove itself in Phase II UPDATE (22/05/2017): Argenx has gone above and beyond to secure $115M (€103M) on the NASDAQ. Underwriters claimed all of the shares offered in over allotment, bringing the IPO to 50% more than the initial goal. Rather a lot for a company whose compound has yet to prove itself in Phase II. UPDATE (24/04/2017): Pricing terms have yet to be set, but the […] May 22, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 May 2017 Celyad gets FDA Fast Track to Tackle Heart Failure with Cell Therapy Celyad has received Fast Track Designation from the FDA for C-Cure, a cell therapy aimed to treat heart failure with the patient’s own stem cells. Celyad is confident that the announcement of Fast Track Designation from the FDA will help it accelerate the search for a partner to develop C-Cure, a cell therapy for ischemic […] May 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 May 2017 Hypermutation could be the Key to Biofuels – and Antibiotic Resistance Instead of taking a spa vacation, stressed out bacteria start mutating their DNA fast. This nearly suicidal behavior can yield a lucky survivor in nature. For us, it could mean new strategies for biofuel production and fighting antibiotic resistance, researchers say. Researchers from the Centre of Microbial and Plant Genetics at KU Leuven, in Belgium, are shining […] May 9, 2017 - 2 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email